【レポートの概要(一部)】
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Epidemiology 10
2.2 Symptoms 10
2.3 Etiology 11
2.4 Pathophysiology 11
2.5 Co-morbidities and Complications 12
2.6 Classification 13
2.7 Prognosis 14
2.8 Diagnosis 14
2.9 Assessing Treatment Effectiveness 16
2.10 Treatment Algorithm 16
2.10.1 The Role of Insulin in Type 2 Diabetes 18
2.10.2 Non-insulin Diabetic Drugs 19
2.10.3 Other Drugs 21
3 Key Marketed Products 22
3.1 Metformin 22
3.2 DPP-4 Inhibitors 23
3.2.1 Januvia (sitagliptin) – Merck & Co 23
3.2.2 Tradjenta (linagliptin) – Boehringer Ingelheim 24
3.2.3 Onglyza (saxagliptin) – Bristol-Myers Squibb and AstraZeneca 25
3.2.4 Nesina (alogliptin) – Takeda 25
3.2.5 Galvus (vildagliptin) – Novartis 26
3.2.6 Tenelia (teneligliptin) – Daiichi Sankyo and Mitsubishi Tanabe 27
3.3 GLP-1 Agonists 28
3.3.1 Byetta and Bydureon (exenatide) – Bristol-Myers Squibb 28
3.3.2 Lyxumia (lixisenatide) – Sanofi 29
3.3.3 Victoza (liraglutide) – Novo Nordisk 30
3.4 Sulfonylureas 31
3.4.1 Glimepiride 31
3.4.2 Gliclazide 31
3.5 Thiazolidinediones 32
3.5.1 Actos (pioglitazone) – Takeda Pharmaceuticals Limited 32
3.5.2 Avandia (rosiglitazone) – GlaxoSmithKline 33
3.6 Long-Acting Insulins 34
3.6.1 Lantus (insulin glargine) – Sanofi 34
3.6.2 Levemir (insulin detemir) – Novo Nordisk 35
3.6.3 Tresiba and Ryzodeg (Insulin degludec) – Novo Nordisk 36
3.7 SGLT-2 Inhibitors 37
3.7.1 Forxiga (dapagliflozin) – Bristol-Myers Squibb 37
3.7.2 Invokana (canagliflozin) – Janssen 37
3.8 Heat Map for Marketed Products 38
4 Pipeline for Type 2 Diabetes 41
4.1 Overall Pipeline 41
4.2 Therapeutic Classes 42
4.3 Rate of Attrition 44
4.3.1 Failure Rate by Molecule Type 44
4.3.2 Failure Rate by Therapeutic Class 45
4.4 Reasons for Failure of Developmental Programs 48
4.5 Clinical Trial Duration 48
4.5.1 Duration by Molecule Type 48
4.5.2 Duration by Therapeutic Class 49
4.6 Clinical Trial Size 51
4.6.1 Clinical Trial Size by Molecule Type 52
4.6.2 Clinical Trial Size by Therapeutic Class 53
4.7 Promising Drugs in the Pipeline 55
4.7.1 LY-2189265 (dulaglutide) – Eli Lilly 55
4.7.2 Albiglutide – GlaxoSmithKline 55
4.7.3 LC15-044 (gemigliptin) – LG Life Sciences 56
4.7.4 TAK-875 – Takeda 56
4.7.5 Ipragliflozin – Astellas Pharma 57
4.7.6 LX-4211 – Lexicon Pharmaceuticals 57
4.7.7 Imeglimin – Poxel SA 58
4.7.8 CCX-140-B – ChemoCentryx 58
4.7.9 Semaglutide – Novo Nordisk A/S 59
4.7.10 PC-DAC Exendin-4 – ConjuChem Biotechnologies 59
4.8 Heat Map for Pipeline Products 59
4.9 Conclusion 62
5 Market Forecast to 2019 64
5.1 Global Market 64
5.1.1 Treatment Usage Patterns 64
5.1.2 Market Size 65
5.2 US 66
5.2.1 Treatment Usage Patterns 66
5.2.2 Annual Cost of Therapy 67
5.2.3 Market Size 67
5.3 Top Five Countries of Europe 68
5.3.1 Treatment Usage Patterns 68
5.3.2 Annual Cost of Therapy 69
5.3.3 Market Size 70
5.4 Japan 72
5.4.1 Treatment Usage Patterns 72
5.4.2 Annual Cost of Therapy 72
5.4.3 Market Size 73
5.5 Drivers and Barriers 73
5.5.1 Drivers 73
5.5.2 Barriers 74
6 Deals and Strategic Consolidations 75
6.1 Licensing Deals 75
6.1.1 TransTech Pharma Enters into Licensing Agreement with Forest Laboratories 78
6.1.2 Xoma Enters into Licensing Agreement with Les Laboratoires Servier for Xoma 052 78
6.1.3 Zealand Pharma Enters into a Licensing and Collaboration Agreement with Boehringer Ingelheim 78
6.1.4 Exelixis Enters into Licensing Agreement with Bristol-Myers Squibb for XL475 79
6.1.5 Prosidion Limited Enters into a Licensing Agreement with Eli Lilly and Company 79
6.1.6 Metabolex Enters into Licensing Agreement with Sanofi 79
6.1.7 Wellstat Enters into a License Agreement with Sanofi 79
6.1.8 CureDM and Lankenau Institute Enter into a Licensing Agreement with Sanofi 79
6.1.9 Metabolex Enters into a Development and Licensing Agreement with Janssen Pharmaceuticals 80
6.1.10 Dainippon Sumitomo Pharma Enters into Licensing Agreement with Intercept Pharma for INT-747 80
6.1.11 Ipsen Enters into Licensing Agreement with F. Hoffmann-La Roche for BIM 51077 80
6.1.12 Glenmark Pharma Enters into Licensing Agreement with Merck KGaA 80
6.1.13 Euroscreen Enters into Licensing Agreement with Janssen Pharmaceuticals 81
6.1.14 Phenomix Enters into Licensing Agreement with Chiesi Farmaceutici 81
6.1.15 Otsuka Pharma Enters into Licensing Agreement with Kyowa Hakko Kirin for Saxagliptin 81
6.1.16 Nastech Pharma Enters into Licensing Agreement with Amylin Pharma 81
6.1.17 Emisphere Technologies Enters into a Licensing Agreement with Novo Nordisk 81
6.1.18 Array BioPharma Enters into a Licensing Agreement with Amgen 82
6.1.19 Theratechnologies Enters into a Licensing Agreement with OctoPlus 82
6.1.20 Diabetica Enters into a Licensing Agreement with Amylin 82
6.1.21 Celtic Therapeutics Enters into a Licensing Agreement with Bellus Health 82
6.1.22 Aradigm Enters into a Licensing Agreement with Novo Nordisk 83
6.1.23 Santarus Enters into a License Agreement with Shore Therapeutics 83
6.1.24 Depomed Enters into a Licensing Agreement with Boehringer Ingelheim 83
6.1.25 Depomed Enters into a Licensing Agreement with Merck 83
6.1.26 Depomed Enters into a Licensing Agreement with Teva 84
6.2 Co-development Deals 84
6.2.1 Eli Lilly Enters into a Co-development Agreement with Boehringer Ingelheim 85
6.2.2 AstraZeneca Enters into Co-development Agreement with Bristol-Myers Squibb 86
6.2.3 Metabolex Enters into a Co-development Agreement with Janssen Pharmaceuticals 86
6.2.4 Amylin Pharma Terminates Co-development Agreement with Eli Lilly for Exenatide 86
6.2.5 Isis Enters into a Collaboration Agreement with Janssen Pharmaceuticals 86
6.2.6 Neurocrine Biosciences Enters into a Collaboration Agreement with Boehringer Ingelheim 87
6.2.7 Intercept Pharma Enters into Co-development Agreement with Servier 87
6.2.8 Transition Therapeutics Enters into an Agreement with Eli Lilly 87
6.2.9 Ambrx Enters into a Co-Development Agreement with Bristol-Myers Squibb 87
6.2.10 Biocompatibles Enters into a Co-Development Agreement with AstraZeneca 88
7 Appendix 89
7.1 All Pipeline Drugs by Stage of Development 89
7.1.1 Discovery 89
7.1.2 Preclinical and IND-filed 91
7.1.3 Phase I 95
7.1.4 Phase II 98
7.1.5 Phase III and Pre-registration 102
7.1.6 Undisclosed 104
7.2 Market Forecasts to 2019 105
7.2.1 Global 105
7.2.2 US 105
7.2.3 UK 106
7.2.4 France 106
7.2.5 Germany 107
7.2.6 Italy 107
7.2.7 Spain 108
7.2.8 Japan 108
7.3 Market Definitions 109
7.4 Abbreviations 109
7.5 References for Heat Maps 112
7.6 References 114
7.7 Research Methodology 119
7.7.1 Coverage 119
7.7.2 Secondary Research 120
7.7.3 Primary Research 120
7.8 Therapeutic Landscape 121
7.9 Epidemiology-based Forecasting 121
7.10 Market Size by Geography 122
7.11 Geographical Landscape 123
7.12 Pipeline Analysis 123
7.13 Expert Panel Validation 123
7.14 Contact Us 123
7.15 Disclaimer 123
【レポート販売概要】
■ タイトル:Type 2 Diabetes Therapeutics Market to 2019 – A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019■ 発行日:2013年10月18日
■ 調査会社:GBI Research
■ 商品コード:GBIR403170034
■ 調査対象地域:グローバル
- ARC Resources Ltd.:石油・ガスの開発・生産動向及びコスト分析- Q1, 2013ARC Resources Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis - Q1, 2013 Summary ARC Resources Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for k …
- 結晶セルロースの世界市場2015Microcrystalline Cellulose (CAS 9004-34-6) Market Research Report 2015 aims at providing comprehensive data on Microcrystalline Cellulose market globally and regionally (Europe, Asia, North America, Latin America etc.) The report includes Microcrystalline Cellulose description, covers its application areas, manufacturing methods, patterns. It captures Microcrystalline Cellulose market trends, pays …
- 危険およびセーフエリア用信号装置(可聴式&可視式)の世界市場予測(~2022):製品別(ストロボビーコン、照明、火災警報/火災報知器)、接続サービス別、産業別、地域別The signaling devices market (audible & visual) was valued at USD 1.49 Billion in 2015 and is expected to reach USD 2.03 Billion by 2022, at a CAGR of 4.43% during the forecast period. The growth of this market is being propelled by the growing focus on industry safety measures and rise in the usage of LED lighting solutions for hazardous and safe areas. The scope of this report covers the signali …
- ソルビトールの世界市場予測(~2021年):液体/シロップ・ソルビトール、結晶/パウダー・ソルビトールThe global sorbitol market is projected to reach USD 1.42 Billion by 2021, at a CAGR of 5.3% from 2016 to 2021. The sorbitol market has witnessed significant growth in the recent years. Features, such as sweetening flavor, non-cariogenic, cooling effect, free flowing powder, excellent compressibility and blend homogeneity, coating, low-calorie, and filler/diluent make sorbitol the most preferred c …
- クロマトグラフィーの世界市場:液体クロマトグラフィー、ガスクロマトグラフィー、イオン交換クロマトグラフィーAbout Chromatography Chromatography is a technique in which a mixture is passed into solution or suspension through a path in which the components move at different rates. It is used to separate the components of a liquid with great accuracy. There are several types of separation techniques such as liquid chromatography, gas chromatography, and electrophoresis. The technique used depends on the so …
- 女性医療診断の世界市場予測(~2021):出生前検査、ダウン症候群検査、HPV検査、受胎能試験、妊娠テスト、 尿路感染症検査、骨粗鬆症検査、乳がん検査、子宮頸がん検査、卵巣がん検査The global women’s health diagnostics market is projected to reach USD 36.64 Billion by 2021 from USD 25.03 Billion in 2016, at a CAGR of around 7.9% during the forecast period. This market is mainly driven by the increased adoption of point-of-care & rapid diagnostic tests, growth in the number of private diagnostic centers, high prevalence of infectious diseases in women, rising incidence of chr …
- EV Energy Partners, L.P.社の石油・ガス開発・生産動向及びコスト分析(2013年第4四半期)EV Energy Partners, L.P. Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2013 Summary EV Energy Partners, L.P. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential …
- IPaaSの世界市場2015-2019About iPaaS iPaaS is a cloud integration platform that integrates application and database. Various activities such as development, execution, and governance of integration process among on-premises or cloud-based applications are taken care of by iPaaS solution. An iPaaS solution includes batch and real-time integration services, API framework, MDM, data quality, and security measures. Most iPaaS …
- 医療産業向け分析・試験サービスの世界市場:安定性試験、原材料試験、方式検証、微生物試験、環境モニタリング、生物分析サービスThe global healthcare analytical testing services market is projected to reach USD 4.13 Billion by 2021 from USD 2.42 Billion in 2016, at a CAGR of 11.3% from 2016 to 2021. The market is expected to witness significant growth in the coming years due to the rising demand for analytical services for biologics and large-molecule drugs. Factors such as increasing outsourcing of analytical testing by p …
- 心房細動(Atrial Fibrillation):疫学予測(~2023)EpiCast Report: Atrial Fibrillation - Epidemiology Forecast to 2023 Summary Atrial fibrillation (AF) is a disorder of the heart’s electrical system. AF is one of the most common cardiovascular diseases among the elderly, worldwide. According to the Global Burden of Disease study, AF affected approximately 33.5 million people, or 0.5% of the world's population, in 2010, of which 20.9 million were m …
- 金属パッケージングの世界市場Visiongain’s comprehensive new 223 page report reveals that the global metal packaging market will achieve revenues of $121.7bn in 2015. Are you involved in the metal packaging market or intend to be? If so, then you must read this report It’s vital that you keep your knowledge up to date. You need this report. Market scope: metal packaging has multiple applications in food, beverage, healthcare, …
- 世界の色素増感電池市場2015The Global Dye Sensitized Cell (DSC) Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Dye Sensitized Cell (DSC) industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Dye Sensitized Cell (DSC) market analysis is provided for the international markets in …
- 血液バンク用機器の世界市場2015This report reviews current instrumentation technologies, and compares features of over 20 leading blood banking automated and semiautomated analyzers.Contains 25 pages
- 倉庫用はしごの世界市場2016-2020About Warehouse Ladders Warehouse operators offer multiple services such as loading and unloading, inventory management tools, and other supply chain management (SCM)-related services. Ladders help industrial and commercial warehouses operate efficiently. Rolling ladders are preferred in industrial warehouses. These ladders are often made of rugged, anti-magnetic, corrosion resistant materials. Ro …
- Sherritt International Corporation:石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Sherritt International Corporation Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Sherritt International Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The rep …